Showing results (151-160 of 283) with videos related to

Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|January 1, 1990
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Biochemical Pharmacology|June 1, 1989
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivoM J Lind, A T McGown, J A Hadfield, et al.
Seminars in Oncology|May 13, 1998
Dose intensity in small cell lung cancerN Thatcher, S M Lee, P J Woll, et al.
Lung Cancer (Amsterdam, Netherlands)|August 5, 2008
Radiotherapy for small-cell lung cancer-Where are we heading?N A Bayman, H Sheikh, B Kularatne, et al.
British Journal of Clinical Pharmacology|January 1, 1991
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patientsL D Lewis, D L Fitzgerald, P Mohan, et al.
British Journal of Cancer|January 1, 1989
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity studyW P Steward, J H Scarffe, R Austin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Ifosfamide by bolus as treatment for advanced non-small cell lung cancerN Thatcher, H Anderson, D B Smith, et al.
Leukemia|November 11, 1999
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapyN Chinnasamy, J Rafferty, L Lashford, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancerM J Lind, S Gomm, A P Simmonds, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.
Pageof 29